Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

546 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial.
Scirica BM, Morrow DA, Bode C, Ruzyllo W, Ruda M, Oude Ophuis AJ, Lopez-Sendon J, Swedberg K, Ogorek M, Rifai N, Lukashevich V, Maboudian M, Cannon CP, McCabe CH, Braunwald E. Scirica BM, et al. Among authors: rifai n. Eur Heart J. 2010 Aug;31(16):1993-2005. doi: 10.1093/eurheartj/ehq190. Epub 2010 Jun 17. Eur Heart J. 2010. PMID: 20558431 Clinical Trial.
Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
Ray KK, Cannon CP, Cairns R, Morrow DA, Rifai N, Kirtane AJ, McCabe CH, Skene AM, Gibson CM, Ridker PM, Braunwald E; PROVE IT-TIMI 22 Investigators. Ray KK, et al. Among authors: rifai n. J Am Coll Cardiol. 2005 Oct 18;46(8):1417-24. doi: 10.1016/j.jacc.2005.08.024. J Am Coll Cardiol. 2005. PMID: 16226164 Free article. Clinical Trial.
Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial).
Bonaca MP, Wiviott SD, Sabatine MS, Buros J, Murphy SA, Scirica BM, Rifai N, Antman EM, Morrow DA. Bonaca MP, et al. Among authors: rifai n. Am J Cardiol. 2007 Feb 1;99(3):344-8. doi: 10.1016/j.amjcard.2006.08.035. Epub 2006 Nov 30. Am J Cardiol. 2007. PMID: 17261395 Clinical Trial.
Synergistic relationship between hyperglycaemia and inflammation with respect to clinical outcomes in non-ST-elevation acute coronary syndromes: analyses from OPUS-TIMI 16 and TACTICS-TIMI 18.
Ray KK, Cannon CP, Morrow DA, Kirtane AJ, Buros J, Rifai N, McCabe CH, Gibson CM, Braunwald E. Ray KK, et al. Among authors: rifai n. Eur Heart J. 2007 Apr;28(7):806-13. doi: 10.1093/eurheartj/ehm010. Epub 2007 Apr 2. Eur Heart J. 2007. PMID: 17403721 Clinical Trial.
Clinical application of C-reactive protein across the spectrum of acute coronary syndromes.
Scirica BM, Morrow DA, Cannon CP, de Lemos JA, Murphy S, Sabatine MS, Wiviott SD, Rifai N, McCabe CH, Braunwald E; Thrombolysis in Myocardial Infarction (TIMI) Study Group. Scirica BM, et al. Among authors: rifai n. Clin Chem. 2007 Oct;53(10):1800-7. doi: 10.1373/clinchem.2007.087957. Epub 2007 Aug 23. Clin Chem. 2007. PMID: 17717132 Clinical Trial.
Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18.
Morrow DA, Sabatine MS, Brennan ML, de Lemos JA, Murphy SA, Ruff CT, Rifai N, Cannon CP, Hazen SL. Morrow DA, et al. Among authors: rifai n. Eur Heart J. 2008 May;29(9):1096-102. doi: 10.1093/eurheartj/ehn071. Epub 2008 Mar 12. Eur Heart J. 2008. PMID: 18339606 Free PMC article. Clinical Trial.
Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death.
Scirica BM, Cannon CP, Sabatine MS, Jarolim P, Sloane S, Rifai N, Braunwald E, Morrow DA; PROVE IT-TIMI 22 Investigators. Scirica BM, et al. Among authors: rifai n. Clin Chem. 2009 Feb;55(2):265-73. doi: 10.1373/clinchem.2008.117192. Epub 2008 Dec 12. Clin Chem. 2009. PMID: 19074516 Clinical Trial.
Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLopidogrel as Adjunctive ReperfusIon TherapY (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28.
Sherwood MW, Morrow DA, Scirica BM, Jiang S, Bode C, Rifai N, Gerszten RE, Gibson CM, Cannon CP, Braunwald E, Sabatine MS. Sherwood MW, et al. Among authors: rifai n. Am Heart J. 2010 Jun;159(6):964-971.e1. doi: 10.1016/j.ahj.2010.03.005. Am Heart J. 2010. PMID: 20569707 Free PMC article. Clinical Trial.
Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22).
Wilson SR, Sabatine MS, Wiviott SD, Ray KK, De Lemos JA, Zhou S, Rifai N, Cannon CP, Morrow DA; TIMI Study Group. Wilson SR, et al. Among authors: rifai n. Am Heart J. 2011 Jun;161(6):1147-55.e1. doi: 10.1016/j.ahj.2011.02.014. Epub 2011 May 11. Am Heart J. 2011. PMID: 21641362 Clinical Trial.
546 results